Shin Nippon Biomedical Laboratories Ltd
TSE:2395
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Shin Nippon Biomedical Laboratories Ltd
Gross Profit
Shin Nippon Biomedical Laboratories Ltd
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Shin Nippon Biomedical Laboratories Ltd
TSE:2395
|
Gross Profit
¥16.2B
|
CAGR 3-Years
13%
|
CAGR 5-Years
17%
|
CAGR 10-Years
16%
|
|
|
Carna Biosciences Inc
TSE:4572
|
Gross Profit
¥388.1m
|
CAGR 3-Years
-32%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-11%
|
|
|
Medinet Co Ltd
TSE:2370
|
Gross Profit
¥106.9m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-17%
|
|
|
CellSource Co Ltd
TSE:4880
|
Gross Profit
¥2.1B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Immuno-Biological Laboratories Co Ltd
TSE:4570
|
Gross Profit
¥725.7m
|
CAGR 3-Years
14%
|
CAGR 5-Years
24%
|
CAGR 10-Years
5%
|
|
|
D
|
DNA Chip Research Inc
TSE:2397
|
Gross Profit
¥570.3m
|
CAGR 3-Years
86%
|
CAGR 5-Years
45%
|
CAGR 10-Years
28%
|
|
Shin Nippon Biomedical Laboratories Ltd
Glance View
Shin Nippon Biomedical Laboratories, Ltd. is a contract research organization providing drug development services including safety research, clinical pharmacology, and clinical trials. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 986 full-time employees. The company went IPO on 2004-03-08. The firm has four business segments. The Preclinical segment is engaged in the verification of the effectiveness and safety of new drugs by conducting tests on experimental animals, cells and bacteria. The Clinical segment is engaged in the verification of the effectiveness and safety of test articles on human. The Translational Research segment is involved in the research and development of pharmaceutical products and related technology, as well as the conduction of preclinical and clinical trials, among others. The Others segment is engaged in information collecting business, the sale of environmental analysis equipment, and the operation of accommodation. As of March 31, 2013, the Company had 27 subsidiaries and one associated company.
See Also
What is Shin Nippon Biomedical Laboratories Ltd's Gross Profit?
Gross Profit
16.2B
JPY
Based on the financial report for Dec 31, 2025, Shin Nippon Biomedical Laboratories Ltd's Gross Profit amounts to 16.2B JPY.
What is Shin Nippon Biomedical Laboratories Ltd's Gross Profit growth rate?
Gross Profit CAGR 10Y
16%
Over the last year, the Gross Profit growth was -1%. The average annual Gross Profit growth rates for Shin Nippon Biomedical Laboratories Ltd have been 13% over the past three years , 17% over the past five years , and 16% over the past ten years .